Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Yuma Therapeutics Corporation
Profile last edited on: 2/17/22      CAGE: 5MAS7      UEI:

Business Identifier: Disease-modifying pharmaceutical compounds targeting the tau pathway for Alzheimer's disease and other neurodegenerative diseases
Year Founded
2009
First Award
2012
Latest Award
2015
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

77 Pond Avenue C1002
Brookline, MA 02445
   (617) 953-4618
   N/A
   www.yumatherapeutics.com
Location: Single
Congr. District: 04
County: Norfolk

Public Profile

Yuma Therapeutics is a privately held biopharmaceutical company focused on developing novel disease-modifying drugs to treat neurodegenerative diseases. The firm develops disease-modifying pharmaceutical compounds to affect the disease progression of Alzheimer's disease and other neurodegenerative diseases. The compounds function through modulating cellular proteostasis to treat the neurodegenerative proteinopathies.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
1
Conversion Rate
100.00%
Phase I Dollars
$200,752
Phase II Dollars
$1,473,584
Total Awarded
$1,674,336

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2015 2 NIH $1,674,336
Project Title: CSF TAU Biomarker-Guided Development of HSP90 Inhibitors for Alzheimer's Disease

Key People / Management

  Yukari Y Perrella -- President

  Patricio Reyes -- Chief Medical Officer

  Martin Williams -- Co-Founder, Executive Chairman of the Board

Company News

There are no news available.